Skip to main content
SpringerLink
Log in

Mouse Models of Human Cancer: Role in Preclinical Testing and Personalized Medicine

  • Chapter
  • First Online:
Genetically Engineered Mice for Cancer Research

  • 1345 Accesses

Abstract

In the last few decades, information about the human genome and the genetic landscape of human cancer has led to therapeutic strategies guided by specific genetic knowledge and executed with molecularly targeted drugs. The era of personalized medicine for cancer treatment is coming of age. Genetic knowledge leads to identification of potential drug targets that in turn is used to develop molecularly targeted therapies for cancer (see Chapter 28). Central to the pursuit of this approach are faithful mouse models of human cancer. As we discuss in this chapter, these models not only serve to define the critical and causal molecular events required for cancer, but they also provide powerful systems for preclinical testing of cancer drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Al-Hajj M, Clarke MF (2004) Self-renewal and solid tumor stem cells. Oncogene 23:7274–7282

    Article  PubMed  CAS  Google Scholar 

  • Alcalay M, Zangrilli D, Fagioli M, Pandolfi PP, Mencarelli A, Lo Coco F, Biondi A, Grignani F, Pelicci PG (1992) Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia. Proc Natl Acad Sci USA 89:4840–4844

    Article  PubMed  CAS  Google Scholar 

  • Alcalay M, Zangrilli D, Pandolfi PP, Longo L, Mencarelli A, Giacomucci A, Rocchi M, Biondi A, Rambaldi A, Lo Coco F et al (1991) Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc Natl Acad Sci USA 88:1977–1981

    Article  PubMed  CAS  Google Scholar 

  • Arnould C, Philippe C, Bourdon V, Gr goire MJ, Berger R, Jonveaux P (1999) The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet 8:1741–1749

    Article  PubMed  CAS  Google Scholar 

  • Arteaga CL (2006) EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. Cancer Cell 9:421–423

    Article  PubMed  CAS  Google Scholar 

  • Backman SA, Ghazarian D, So K, Sanchez O, Wagner KU, Hennighausen L, Suzuki A, Tsao MS, Chapman WB, Stambolic V et al (2004) Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc Natl Acad Sci USA 101:1725–1730

    Article  PubMed  CAS  Google Scholar 

  • Backman SA, Stambolic V, Suzuki A, Haight J, Elia A, Pretorius J, Tsao MS, Shannon P, Bolon B, Ivy GO et al (2001) Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat Genet 29:396–403

    Article  PubMed  CAS  Google Scholar 

  • Bayascas JR, Leslie NR, Parsons R, Fleming S, Alessi DR (2005) Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/−) mice. Curr Biol 15:1839–1846

    Article  PubMed  CAS  Google Scholar 

  • Berger AH, Niki M, Morotti A, Taylor BS, Socci ND, Viale A, Brennan C, Szoke J, Motoi N, Rothman PB et al (2010) Identification of DOK genes as lung tumor suppressors. Nat Genet 42(3):216–223

    Article  PubMed  CAS  Google Scholar 

  • Borrow J, Goddard AD, Sheer D, Solomon E (1990) Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 249:1577–1580

    Article  PubMed  CAS  Google Scholar 

  • Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG, Atwater S, Bishop JM (1997) A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 94:2551–2556

    Article  PubMed  CAS  Google Scholar 

  • Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC et al (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118:3065–3074

    PubMed  CAS  Google Scholar 

  • Carver BS, Pandolfi PP (2006) Mouse modeling in oncologic preclinical and translational research. Clin Cancer Res 12:5305–5311

    Article  PubMed  CAS  Google Scholar 

  • Caterina N, Andrea L, Akash P, Lewis CC, Pier PP Cancer Discovery July 2011 1:108–116; doi:10.1158/2159-8290.CD-11-0061

    Article  PubMed  CAS  Google Scholar 

  • Chen ML, Xu PZ, Peng XD, Chen WS, Guzman G, Yang X, Di Cristofano A, Pandolfi PP, Hay N (2006) The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/− mice. Genes Dev 20:1569–1574

    Article  PubMed  CAS  Google Scholar 

  • Chen Z, Brand NJ, Chen A, Chen SJ, Tong JH, Wang ZY, Waxman S, Zelent A (1993) Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J 12:1161–1167

    PubMed  CAS  Google Scholar 

  • Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W et al (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436:725–730

    Article  PubMed  CAS  Google Scholar 

  • Cheng GX, Zhu XH, Men XQ, Wang L, Huang QH, Jin XL, Xiong SM, Zhu J, Guo WM, Chen JQ et al (1999) Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha. Proc Natl Acad Sci USA 96:6318–6323

    Article  PubMed  CAS  Google Scholar 

  • Cheng L, Ramesh AV, Flesken-Nikitin A, Choi J, Nikitin AY (2010) Mouse models for cancer stem cell research. Toxicol Pathol 38:62–71

    Article  PubMed  Google Scholar 

  • Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, Somwar R, Golas B, Wang L, Motoi N, Szoke J et al (2009) An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 28:2773–2783

    Article  PubMed  CAS  Google Scholar 

  • de The H, Chomienne C, Lanotte M, Degos L, Dejean A (1990) The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 347:558–561

    Article  PubMed  Google Scholar 

  • de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A (1991) The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66:675–684

    Article  PubMed  Google Scholar 

  • Di Cristofano A, Pandolfi PP (2000) The multiple roles of PTEN in tumor suppression. Cell 100:387–390

    Article  PubMed  Google Scholar 

  • Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP (1998) Pten is essential for embryonic development and tumour suppression. Nat Genet 19:348–355

    Article  PubMed  Google Scholar 

  • Dick JE (2009) Looking ahead in cancer stem cell research. Nat Biotechnol 27:44–46

    Article  PubMed  CAS  Google Scholar 

  • Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB et al (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069–1075

    Article  PubMed  CAS  Google Scholar 

  • Druker BJ (2008) Translation of the Philadelphia chromosome into therapy for CML. Blood 112:4808–4817

    Article  PubMed  CAS  Google Scholar 

  • Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y et al (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351–1356

    Article  PubMed  CAS  Google Scholar 

  • Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE et al (2007a) PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67:11924–11932

    Article  PubMed  CAS  Google Scholar 

  • Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J et al (2007b) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039–1043

    Article  PubMed  CAS  Google Scholar 

  • Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, Shokat KM, Weiss WA (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9:341–349

    Article  PubMed  CAS  Google Scholar 

  • Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ, Whitsett JA, Koretsky A, Varmus HE (2001) Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15:3249–3262

    Article  PubMed  CAS  Google Scholar 

  • Fraser MM, Zhu X, Kwon CH, Uhlmann EJ, Gutmann DH, Baker SJ (2004) Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res 64:7773–7779

    Article  PubMed  CAS  Google Scholar 

  • Goddard AD, Borrow J, Freemont PS, Solomon E (1991) Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 254:1371–1374

    Article  PubMed  CAS  Google Scholar 

  • Gray IC, Stewart LM, Phillips SM, Hamilton JA, Gray NE, Watson GJ, Spurr NK, Snary D (1998) Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer 78:1296–1300

    Article  PubMed  CAS  Google Scholar 

  • Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ (1997) Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 89:376–387

    PubMed  CAS  Google Scholar 

  • Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9–22

    Article  PubMed  CAS  Google Scholar 

  • Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, Mullholland DJ, Magnuson MA, Wu H, Sabatini DM (2009) mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15:148–159

    Article  PubMed  CAS  Google Scholar 

  • Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR et al (2004) The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166:213–223

    Article  PubMed  CAS  Google Scholar 

  • He LZ, Bhaumik M, Tribioli C, Rego EM, Ivins S, Zelent A, Pandolfi PP (2000) Two critical hits for promyelocytic leukemia. Mol Cell 6:1131–1141

    Article  PubMed  CAS  Google Scholar 

  • He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, Pandolfi PP (1998) Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet 18:126–135

    Article  PubMed  CAS  Google Scholar 

  • He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP Jr, Rifkind RA, Marks PA, Richon VM, Pandolfi PP (2001) Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 108:1321–1330

    PubMed  CAS  Google Scholar 

  • He LZ, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, Soares V, Cattoretti G, Pandolfi PP (1997) Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci USA 94:5302–5307

    Article  PubMed  CAS  Google Scholar 

  • Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W et al (2009) Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 106:3342–3347

    Article  PubMed  CAS  Google Scholar 

  • Hummel JL, Wells RA, Dube ID, Licht JD, Kamel-Reid S (1999) Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia. Oncogene 18:633–641

    Article  PubMed  CAS  Google Scholar 

  • Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, Rosenblatt J, Avigan DE, Teruya-Feldstein J, Pandolfi PP (2008) PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453:1072–1078

    Article  PubMed  CAS  Google Scholar 

  • Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15:3243–3248

    Article  PubMed  CAS  Google Scholar 

  • Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R et al (2006) The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9:485–495

    Article  PubMed  CAS  Google Scholar 

  • Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA et al (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448:807–810

    Article  PubMed  CAS  Google Scholar 

  • Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM et al (2008) Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454:776–779

    PubMed  CAS  Google Scholar 

  • Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T (2001) Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410:1111–1116

    Article  PubMed  CAS  Google Scholar 

  • Jordan CT, Guzman ML, Noble M (2006) Cancer stem cells. N Engl J Med 355:1253–1261

    Article  PubMed  CAS  Google Scholar 

  • Jordan VC (2008) Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer 44:30–38

    Article  PubMed  CAS  Google Scholar 

  • Joyce JA (2005) Therapeutic targeting of the tumor microenvironment. Cancer Cell 7:513–520

    Article  PubMed  CAS  Google Scholar 

  • Kakizuka A, Miller WH Jr, Umesono K, Warrell RP Jr, Frankel SR, Murty VV, Dmitrovsky E, Evans RM (1991) Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66:663–674

    Article  PubMed  CAS  Google Scholar 

  • Kastner P, Perez A, Lutz Y, Rochette-Egly C, Gaub MP, Durand B, Lanotte M, Berger R, Chambon P (1992) Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. EMBO J 11:629–642

    PubMed  CAS  Google Scholar 

  • Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C et al (2008) Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 118:3051–3064

    PubMed  CAS  Google Scholar 

  • Kissil JL, Walmsley MJ, Hanlon L, Haigis KM, Bender Kim CF, Sweet-Cordero A, Eckman MS, Tuveson DA, Capobianco AJ, Tybulewicz VL et al (2007) Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Res 67:8089–8094

    Article  PubMed  CAS  Google Scholar 

  • Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B et al (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125:733–747

    Article  PubMed  CAS  Google Scholar 

  • Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786–792

    Article  PubMed  CAS  Google Scholar 

  • Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, Liu X, Wu H (2002) Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 32:148–149

    Article  PubMed  CAS  Google Scholar 

  • Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL et al (2007) Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 12:81–93

    Article  PubMed  CAS  Google Scholar 

  • Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, Michaux JL, Wu Y, DeBlasio A, Miller WH Jr et al (1995) Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 85:1083–1094

    PubMed  CAS  Google Scholar 

  • Longo L, Pandolfi PP, Biondi A, Rambaldi A, Mencarelli A, Lo Coco F, Diverio D, Pegoraro L, Avanzi G, Tabilio A et al (1990) Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias. J Exp Med 172:1571–1575

    Article  PubMed  CAS  Google Scholar 

  • Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139

    Article  PubMed  CAS  Google Scholar 

  • Ma L, Teruya-Feldstein J, Behrendt N, Chen Z, Noda T, Hino O, Cordon-Cardo C, Pandolfi PP (2005a) Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev 19:1779–1786

    Article  PubMed  CAS  Google Scholar 

  • Ma X, Ziel-van der Made AC, Autar B, van der Korput HA, Vermeij M, van Duijn P, Cleutjens KB, de Krijger R, Krimpenfort P, Berns A et al (2005b) Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 65:5730–5739

    Article  PubMed  CAS  Google Scholar 

  • Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K et al (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7:1851–1863

    Article  PubMed  CAS  Google Scholar 

  • Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC (2005) Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 19:1773–1778

    Article  PubMed  CAS  Google Scholar 

  • Marino S, Krimpenfort P, Leung C, van der Korput HA, Trapman J, Camenisch I, Berns A, Brandner S (2002) PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum. Development 129:3513–3522

    PubMed  CAS  Google Scholar 

  • Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720–724

    Article  PubMed  CAS  Google Scholar 

  • Nardella C, Carracedo A, Alimonti A, Hobbs RM, Clohessy JG, Chen Z, Egia A, Fornari A, Fiorentino M, Loda M et al (2009) Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci Signal 2:ra2

    Article  PubMed  CAS  Google Scholar 

  • Nardella C, Chen Z, Salmena L, Carracedo A, Alimonti A, Egia A, Carver B, Gerald W, Cordon-Cardo C, Pandolfi PP (2008) Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev 22:2172–2177

    Article  PubMed  CAS  Google Scholar 

  • Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500

    Article  PubMed  CAS  Google Scholar 

  • Pandolfi PP, Grignani F, Alcalay M, Mencarelli A, Biondi A, LoCoco F, Pelicci PG (1991) Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 6:1285–1292

    PubMed  CAS  Google Scholar 

  • Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306–13311

    Article  PubMed  CAS  Google Scholar 

  • Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H (2005a) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73

    Article  PubMed  CAS  Google Scholar 

  • Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE (2005b) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17

    Article  PubMed  CAS  Google Scholar 

  • Peng C, Li S (2010) CML mouse model in translational research. Methods Mol Biol 602:253–266

    Article  PubMed  CAS  Google Scholar 

  • Perez A, Kastner P, Sethi S, Lutz Y, Reibel C, Chambon P (1993) PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. EMBO J 12:3171–3182

    PubMed  CAS  Google Scholar 

  • Perez-Caro M, Sanchez-Garcia I (2006) Killing time for cancer stem cells (CSC): discovery and development of selective CSC inhibitors. Curr Med Chem 13:1719–1725

    Article  PubMed  CAS  Google Scholar 

  • Petti MC, Fazi F, Gentile M, Diverio D, De Fabritiis P, De Propris MS, Fiorini R, Spiriti MA, Padula F, Pelicci PG et al (2002) Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies. Blood 100:1065–1067

    Article  PubMed  CAS  Google Scholar 

  • Piazza F, Gurrieri C, Pandolfi PP (2001) The theory of APL. Oncogene 20:7216–7222

    Article  PubMed  CAS  Google Scholar 

  • Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R (1999) Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 96:1563–1568

    Article  PubMed  CAS  Google Scholar 

  • Politi K, Fan PD, Shen R, Zakowski M, Varmus H (2010) Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. Dis Model Mech 3:111–119

    Article  PubMed  CAS  Google Scholar 

  • Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE (2006) Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20:1496–1510

    Article  PubMed  CAS  Google Scholar 

  • Pollock JL, Westervelt P, Kurichety AK, Pelicci PG, Grisolano JL, Ley TJ (1999) A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia. Proc Natl Acad Sci USA 96:15103–15108

    Article  PubMed  CAS  Google Scholar 

  • Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, Henley A, Di-Stefano F, Ahmad Z, Guillard S et al (2007) Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 67:5840–5850

    Article  PubMed  CAS  Google Scholar 

  • Redner RL (2002) Variations on a theme: the alternate translocations in APL. Leukemia 16:1927–1932

    Article  PubMed  CAS  Google Scholar 

  • Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ (1996) The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 87:882–886

    PubMed  CAS  Google Scholar 

  • Regales L, Balak MN, Gong Y, Politi K, Sawai A, Le C, Koutcher JA, Solit DB, Rosen N, Zakowski MF et al (2007) Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS One 2:e810

    Article  PubMed  CAS  Google Scholar 

  • Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK et al (2009) Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 119:3000–3010

    PubMed  CAS  Google Scholar 

  • Rego EM, He LZ, Warrell RP Jr, Wang ZG, Pandolfi PP (2000) Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci USA 97:10173–10178

    Article  PubMed  CAS  Google Scholar 

  • Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111

    Article  PubMed  CAS  Google Scholar 

  • Shah OJ, Wang Z, Hunter T (2004) Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 14:1650–1656

    Article  PubMed  CAS  Google Scholar 

  • Shigematsu H, Gazdar AF (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118:257–262

    Article  PubMed  CAS  Google Scholar 

  • Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561–566

    Article  PubMed  CAS  Google Scholar 

  • Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, Ueno T, Haruta H, Hamada T, Yamashita Y, Ishikawa Y et al (2008) A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 105:19893–19897

    Article  PubMed  CAS  Google Scholar 

  • Solomon B, Varella-Garcia M, Camidge DR (2009) ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 4:1450–1454

    Article  PubMed  Google Scholar 

  • Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95:29–39

    Article  PubMed  CAS  Google Scholar 

  • Sukhai MA, Wu X, Xuan Y, Zhang T, Reis PP, Dube K, Rego EM, Bhaumik M, Bailey DJ, Wells RA et al (2004) Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RARalpha. Oncogene 23:665–678

    Article  PubMed  CAS  Google Scholar 

  • Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W et al (1998) High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 8:1169–1178

    Article  PubMed  CAS  Google Scholar 

  • Suzuki A, Yamaguchi MT, Ohteki T, Sasaki T, Kaisho T, Kimura Y, Yoshida R, Wakeham A, Higuchi T, Fukumoto M et al (2001) T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14:523–534

    Article  PubMed  CAS  Google Scholar 

  • Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, Mesirov J, Golub TR, Jacks T (2005) An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 37:48–55

    PubMed  CAS  Google Scholar 

  • Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T et al (2003) Pten dose dictates cancer progression in the prostate. PLoS Biol 1:E59

    Article  PubMed  Google Scholar 

  • Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D et al (2004) Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5:375–387

    Article  PubMed  CAS  Google Scholar 

  • Vogelstein B, Kinzler KW (1993) The multistep nature of cancer. Trends Genet 9:138–141

    Article  PubMed  CAS  Google Scholar 

  • Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS et al (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4:209–221

    Article  PubMed  CAS  Google Scholar 

  • Warrell RP Jr (1996) Pathogenesis and management of acute promyelocytic leukemia. Annu Rev Med 47:555–565

    Article  PubMed  CAS  Google Scholar 

  • Warrell RP Jr, de The H, Wang ZY, Degos L (1993) Acute promyelocytic leukemia. N Engl J Med 329:177–189

    Article  PubMed  CAS  Google Scholar 

  • Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP (1998) Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90:1621–1625

    Article  PubMed  CAS  Google Scholar 

  • Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA et al (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450:893–898

    Article  PubMed  CAS  Google Scholar 

  • Wells RA, Catzavelos C, Kamel-Reid S (1997) Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet 17:109–113

    Article  PubMed  CAS  Google Scholar 

  • Wong KK (2007) HKI-272 in non small cell lung cancer. Clin Cancer Res 13:s4593–s4596

    Article  PubMed  CAS  Google Scholar 

  • Wu X, Pandolfi PP (2001) Mouse models for multistep tumorigenesis. Trends Cell Biol 11:S2–S9

    PubMed  CAS  Google Scholar 

  • Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124:471–484

    Article  PubMed  CAS  Google Scholar 

  • Xiao A, Yin C, Yang C, Di Cristofano A, Pandolfi PP, Van Dyke T (2005) Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation. Cancer Res 65:5172–5180

    Article  PubMed  CAS  Google Scholar 

  • Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, Morrison SJ (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441:475–482

    Article  PubMed  CAS  Google Scholar 

  • Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105:2070–2075

    Article  PubMed  CAS  Google Scholar 

  • Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, Griffin JD, Kwiatkowski DJ (2007) PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 117:730–738

    Article  PubMed  CAS  Google Scholar 

  • Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, Vazquez F, Carpenter CL, Kwiatkowski DJ (2003) Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 112:1223–1233

    PubMed  CAS  Google Scholar 

  • Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross JT, Haug JS, Rupp D, Porter-Westpfahl KS, Wiedemann LM et al (2006) PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441:518–522

    Article  PubMed  CAS  Google Scholar 

  • Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R et al (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462:1070–1074

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Departments of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    Alice Hawley Berger & Pier Paolo Pandolfi

  2. Weill Graduate School of Medical Sciences, Cornell University, New York, NY, USA

    Alice Hawley Berger & Pier Paolo Pandolfi

Authors
  1. Alice Hawley Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pier Paolo Pandolfi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pier Paolo Pandolfi .

Editor information

Editors and Affiliations

  1. , Laboratory Of Cancer Biology and Genetic, National Cancer Institute, Convent Dr. 37, Bethesda, 20892, Maryland, USA

    Jeffrey E. Green

  2. National Cancer Institute, Center for Cancer Research, National Institutes of Health, South Drive 50, Bethesda, 20892, Maryland, USA

    Thomas Ried

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Berger, A.H., Pandolfi, P.P. (2012). Mouse Models of Human Cancer: Role in Preclinical Testing and Personalized Medicine. In: Green, J., Ried, T. (eds) Genetically Engineered Mice for Cancer Research. Springer, New York, NY. https://doi.org/10.1007/978-0-387-69805-2_27

Download citation

Publish with us

Policies and ethics

Search

Navigation